Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia

Blood Adv. 2019 Nov 26;3(22):3499-3502. doi: 10.1182/bloodadvances.2019000700.

Abstract

  1. Larotrectinib can be effective in patients with ETV6-NTRK3–positive B-cell lymphoblastic leukemia, inducing prolonged molecular remission.

  2. Single-agent tyrosine kinase inhibitor treatment could be a valuable treatment option in subgroups of kinase fusion–positive ALL patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Combined Modality Therapy
  • Disease Models, Animal
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Mice
  • Molecular Targeted Therapy
  • Oncogene Proteins, Fusion / antagonists & inhibitors
  • Oncogene Proteins, Fusion / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Proteins / antagonists & inhibitors*
  • Proteins / genetics*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Recurrence
  • Retreatment
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Substances

  • ETV6-NTRK3 fusion protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Proteins
  • Pyrazoles
  • Pyrimidines
  • TFG protein, human
  • larotrectinib